Ask Our Experts

Advances in Breast Cancer Screening and Surveillance

References

  1. US Preventive Services Task Force. Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 331, 1918–1930 (2024).
  2. Monticciolo, D. L., Newell, M. S., Moy, L., Lee, C. S. & Destounis, S. V. Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the ACR. J. Am. Coll. Radiol. JACR 20, 902–914 (2023).
  3. ACS Breast Cancer Screening Guidelines. https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html.
  4. Gommers, J. et al. Interval cancer, sensitivity, and specificity comparing AI-supported mammography screening with standard double reading without AI in the MASAI study: a randomised, controlled, non-inferiority, single-blinded, population-based, screening-accuracy trial. The Lancet 407, 505–514 (2026).
  5. Chang, Y.-W. et al. Artificial intelligence for breast cancer screening in mammography (AI-STREAM): preliminary analysis of a prospective multicenter cohort study. Nat. Commun. 16, 2248 (2025).
  6. Treatment of Breast Cancer by Stage – NCI. https://www.cancer.gov/types/breast/treatment/by-stage (2025).
  7. Nahleh, Z. et al. Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update. J. Clin. Oncol. 0, JCO-26-01700 (2026).
  8. Ghezzi, P. et al. Impact of Follow-up Testing on Survival and Health-Related Quality of Life in Breast Cancer Patients: A Multicenter Randomized Controlled Trial. JAMA 271, 1587–1592 (1994).
  9. Del Turco, M. R. et al. Intensive Diagnostic Follow-up After Treatment of Primary Breast Cancer: A Randomized Trial. JAMA 271, 1593–1597 (1994).
  10. Schumacher, J. R. et al. Surveillance Imaging vs Symptomatic Recurrence Detection and Survival in Stage II-III Breast Cancer (AFT-01). JNCI J. Natl. Cancer Inst. 114, 1371–1379 (2022).
  11. Nader-Marta, G. et al. Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis. ESMO Open 9, 102390 (2024).
  12. Shaw, J. A. et al. Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer. JCO Precis. Oncol. 8, e2300456 (2024).
  13. You, H., He, J. & Tian, T. Accuracy of ctDNA-based minimal residual disease detection in predicting postoperative recurrence of breast cancer: a meta-analysis. Front. Oncol. 16, (2026).
  14. Cunningham, N. et al. Tissue-Free vs Tumor-Informed ctDNA Assays for Molecular Residual Disease Detection in Early Triple Negative Breast Cancer. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2026.2833 (2026) doi:10.1001/jamaoncol.2026.2833.
  15. Elliott, M. J. et al. Longitudinal ctDNA tracking in early and recurrent breast cancer using an ultrasensitive structural variant-based assay: an extended analysis from the TRACER study. ESMO Open 11, 108337 (2026).
  16. Turner, N. C. et al. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 34, 200–211 (2023).
  17. Ganguli, I. et al. Cascades of Care After Incidental Findings in a US National Survey of Physicians. JAMA Netw. Open 2, e1913325 (2019).
  18. Sodickson, A. et al. Recurrent CT, Cumulative Radiation Exposure, and Associated Radiation-induced Cancer Risks from CT of Adults. Radiology 251, 175–184 (2009).

DISCLAIMER
This report and all other information and guidance provided by Private Health Management are not to be used or relied on for any diagnostic or treatment purposes. This report and all other information and guidance are not intended to substitute for individualized medical advice, diagnosis or treatment by a physician who is aware of an individual’s medical history and has had an opportunity to conduct an examination. Do not rely on this report in place of seeking professional medical advice.

Pages: 1 2
See More New Stories
Audra Haughton

Audra Haughton, MS, PA-C

Clinical Director | Physician Assistant

Audra Haughton is a Clinical Director at Private Health Management and a board-certified Physician Assistant. She began her career in inpatient medicine before specializing in oncology, with a focus on solid tumors and breast cancer. Prior to PHM, Audra practiced at Memorial Sloan Kettering Cancer Center, where she gained extensive experience managing complex oncology patients and collaborating with multidisciplinary teams to deliver comprehensive care. She earned her Master of Science in Physician Assistant Studies from Long Island University and her Bachelor of Science in Health and Nutrition Sciences from Brooklyn College, CUNY. She is licensed in New York State and certified by the National Commission on Certification of Physician Assistants.
Ross Keller

Ross Keller, PhD

Senior Research Director

Ross Keller is a Senior Research Director at Private Health Management, specializing in cancer biology, focusing on cancer genomics and tumor evolution. Throughout his career, he has utilized cancer models to identify vulnerabilities, aiming to enhance existing translational medicine approaches. Before joining PHM, Ross was a Research Fellow at Memorial Sloan Kettering Cancer Center. There, he studied brain cancer and developed novel treatment regimens using genetically engineered models to mimic human disease. His graduate studies focused on tumor evolution, investigating how environmental radiation exposure can lead to mutations in breast cancer. His work also assessed the impact of targeted treatment regimens on tumor regression and relapse. Ross earned his PhD in Biomedical Sciences from Pennsylvania State University and holds a Bachelor of Arts in Biology and Chemistry from St. Olaf College.
Julie Nowicki

Julie Nowicki, PhD

Science Communications Specialist

Julie is a Science Communications Specialist at Private Health Management, where she collaborates with the Research and Clinical teams to translate complex scientific concepts into clear, accessible information for clients and their families. Her work helps bridge the gap between cutting-edge research and personalized patient care. A scientific and medical writer by training, Julie has developed content for both clinical and patient audiences across a range of therapeutic areas, including oncology, hematology, dermatology, and women’s health. Before joining PHM, she served as a Senior Medical Writer, where she created clinical manuscripts, abstracts, congress materials, and educational resources for pharmaceutical clients. Julie earned her PhD in Cell, Molecular, and Developmental Biology from the University of North Carolina at Chapel Hill.